The DOI matches its Crossref record; 376 of the 376 references it cites were found in a registry or an index.
Advances in the Treatment of Prolactinomas
Abstract
Prolactinomas account for approximately 40% of all pituitary adenomas and are an important cause of hypogonadism and infertility. The ultimate goal of therapy for prolactinomas is restoration or achievement of eugonadism through the normalization of hyperprolactinemia and control of tumor mass. Medical therapy with dopamine agonists is highly effective in the majority of cases and represents the mainstay of therapy. Recent data indicating successful withdrawal of these agents in a subset of patients challenge the previously held concept that medical therapy is a lifelong requirement. Complicated situations, such as those encountered in resistance to dopamine agonists, pregnancy, and giant or malignant prolactinomas, may require multimodal therapy involving surgery, radiotherapy, or both. Progress in elucidating the mechanisms underlying the pathogenesis of prolactinomas may enable future development of novel molecular therapies for treatment-resistant cases. This review provides a critical analysis of the efficacy and safety of the various modes of therapy available for the treatment of patients with prolactinomas with an emphasis on challenging situations, a discussion of the data regarding withdrawal of medical therapy, and a foreshadowing of novel approaches to therapy that may become available in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–376 of 376
Prolactinoma in 53 men: Clinical characteristics and modes of treatment (male prolactinoma)
Berezin, M., Shimon, I., & Hadani, M. (1995) · Journal of Endocrinological Investigation · doi:10.1007/bf03349742 · Cited by 103
Dopamine Resistance of Prolactinomas
Molitch, M. E. (2003) · Pituitary · doi:10.1023/a:1026225625897 · Cited by 102
Self-citationFrequent loss of the P16INK4a gene product in human pituitary tumors.
Woloschak, M., Yu, A., Xiao, J., & Post, K. D. (1996) · PubMed · Cited by 102
CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas
Leong, K. S., Foy, P. M., Swift, A. C., Atkin, S. L., Hadden, D. R., & MacFarlane, I. A. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00901.x · Cited by 102
Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization
Colao, A., Somma, C. D., Loche, S., Sarno, A. D., Klain, M., Pivonello, R., Pietrosante, M., Salvatore, M., & Lombardi, G. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00902.x · Cited by 102
Self-citationSelective Transsphenoidal Adenomectomy in Women With Galactorrhea-Amenorrhea
Post, K. D. (1979) · JAMA · doi:10.1001/jama.1979.03300020028020 · Cited by 101
Barkan, A. L., & Chandler, W. F. (1998) · Neurosurgery · doi:10.1097/00006123-199804000-00126 · Cited by 101
The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas.
Finelli, P., Pierantoni, G. M., Giardino, D. L., Losa, M., Rodeschini, O., Fedele, M., Valtorta, E., Mortini, P., Croce, C. M., Larizza, L., et al. (2002) · PubMed · Cited by 100
Abbud-Antaki, R., Takumi, I., Barker, E. M., Ren, S.-G., Chen, D.-Y., Wawrowsky, K., & Melmed, S. K. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0403 · Cited by 100
Cabergoline-Related Severe Restrictive Mitral Regurgitation
Pinero, A., Marcos‐Alberca, P., & Fortes, J. (2005) · New England Journal of Medicine · doi:10.1056/nejm200511033531822 · Cited by 98
Sarno, A. D., Landi, M. L., Marzullo, P., Somma, C. D., Pivonello, R., Cerbone, G., Lombardi, G., & Colao, A. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01016.x · Cited by 98
Self-citationProlactinomas in Male and Female Patients: A Comparative Clinicopathologic Study
Calle-Rodrigue, R., Giannini, C., Scheithauer, B. W., Lloyd, R. V., Wollan, P. C., Kovács, K., Ştefăneanu, L., Ebright, A. B., Abboud, C. F., & Davis, D. H. (1998) · Mayo Clinic Proceedings · doi:10.4065/73.11.1046 · Cited by 98
Corenblum, B., & Donovan, L. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55819-1 · Cited by 97
Delgrange, E., Maiter, D. M., & Donckier, J. E. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1340454 · Cited by 97
Colao, A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.6.2247 · Cited by 97
Self-citationNormal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors
Friedman, E., Adams, E. F., Höög, A., Gejman, P. V., Carson, E., Larsson, C., Marco, L. A. D., Werner, S., Fahlbusch, R., & Nordenskjöld, M. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.3.568 · Cited by 96
Dopamine, the dopamine D2 receptor and pituitary tumours
Wood, D., Johnston, J., & Johnston, D. G. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb00928.x · Cited by 96
Loss of Vision after Transsphenoidal Surgery
Barrow, D. L., & Tindall, G. T. (1990) · Neurosurgery · doi:10.1227/00006123-199007000-00008 · Cited by 96
Pituitary tumors and pregnancy
Molitch, M. E. (2003) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(03)00054-6 · Cited by 95
Self-citationGillam, M. P., Middler, S. A., Freed, D. J., & Molitch, M. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020426 · Cited by 95
Self-citationTreatment of prolactinomas with megavoltage radiotherapy.
Grossman, A. B., Cohen, B. L., Charlesworth, M., et al. (1984) · BMJ · doi:10.1136/bmj.288.6424.1105 · Cited by 94
Tic reduction with pergolide in a randomized controlled trial in children
Gilbert, D. L., Dure, L., Sethuraman, G., Raab, D., Lane, J., & Sallee, F. R. (2003) · Neurology · doi:10.1212/01.wnl.0000044058.64647.7e · Cited by 93
Hyperprolactinemia, Amenorrhea, and Galactorrhea: A Retrospective Assessment of Twenty-five Cases
KOPPELMAN, M. C. S., JAFFE, M. J., RIETH, K. G., CARUSO, R. C., & LORIAUX, D. L. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-1-115 · Cited by 92
Gamma-Knife Surgery for Secreting Pituitary Adenomas
Morange, I., Régis, J. M., Dufour, H., Andrieu, J., Grisoli, F., Jaquet, P., & Péragut, J. C. (1998) · Acta Neurochirurgica · doi:10.1007/s007010050121 · Cited by 91
Nerve growth factor suppresses the transforming phenotype of human prolactinomas.
Missale, C., Boroni, F., Losa, M., Giovanelli, M. A., Zanellato, A., Toso, R. D., Balsari, A., & Spano, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.7961 · Cited by 90
Giant pituitary adenomas: clinical characteristics and surgical results
Garibi, J., Pomposo, I., Villar, G., & Gaztambide, S. (2002) · British Journal of Neurosurgery · doi:10.1080/02688690220131723 · Cited by 89
Johnston, D. G., Prescott, R. W. G., Kendall‐Taylor, P., Hall, K., Crombie, A. L., Hall, R., McGregor, A. M., Watson, M. J., & Cook, D. B. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90418-7 · Cited by 87
Rosa, M. D., Zarrilli, S., Vitale, G., Somma, C. D., Orio, F., Tauchmanovà, L., Lombardi, G., & Colao, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030852 · Cited by 87
Self-citation“Hook Effect” in Prolactinomas: Case Report and Review of Literature
Frieze, T. W., Mong, D. P., & Koops, M. K. (2002) · Endocrine Practice · doi:10.4158/ep.8.4.296 · Cited by 86
CICCARELLI, E., Giusti, M., Miola, C., POTENZONI, F., Sghedoni, D., Camanni, F., & Giordano, G. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-4-725 · Cited by 86
Sudden uncontrollable somnolence and medication use in Parkinson disease.
Avorn, J., Schneeweiss, S., Sudarsky, L., Benner, J., Kiyota, Y., Levin, R., & Glynn, R. (2005) · Archives of Neurology · doi:10.1001/archneur.62.8.1242 · Cited by 86
Pituitary hyperplasia induced by ectopic expression of nerve growth factor.
Borrelli, E., Sawchenko, P. E., & Evans, R. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2764 · Cited by 85
Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women
Crosignani, P. G., MATTEI, A. M., Severini, V., Cavioni, V., Maggioni, P., & Testa, G. (1992) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0028-2243(92)90094-f · Cited by 85
Ren, S.-G., Kim, S., Taylor, J., Dong, J., Moreau, J.-P., Culler, M. D., & Melmed, S. K. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030302 · Cited by 85
Fiorentini, C., Guerra, N., Facchetti, M., Finardi, A., Tiberio, L., Schiaffonati, L., Spano, P., & Missale, C. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.2.0773 · Cited by 82
Pituitary Tumors and Gamma Knife Surgery - Clinical Experience with More Than Two Years of Follow-Up
Martínez, R., Bravo, G., Burzaco, J., et al. (1998) · Stereotactic and Functional Neurosurgery · doi:10.1159/000056413 · Cited by 81
Giant Invasive Prolactinoma: A Case Report and Review of Nine Further Cases
Davis, J. R., Sheppard, M. C., & Heath, D. A. (1990) · QJM · doi:10.1093/oxfordjournals.qjmed.a068431 · Cited by 80
Prolactin-producing microadenomas in pregnancy.
Divers, W. A., & Yen, S. S. C. (1983) · PubMed · Cited by 79
The Novel Somatostatin Ligand (SOM230) Regulates Human and Rat Anterior Pituitary Hormone Secretion
Murray, R. D., Kim, K., Ren, S.-G., Lewis, I., Weckbecker, G., Bruns, C., & Melmed, S. K. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031319 · Cited by 79
LONG‐TERM TREATMENT OF HYPERPROLACTINAEMIA WITH BROMOCRIPTINE: EFFECT OF DRUG WITHDRAWAL
Wang, C.-L., Lam, K. S. L., C., J. T., et al. (1987) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1987.tb01163.x · Cited by 78
Somatostatin Receptors in Pituitary Function, Diagnosis and Therapy
Hofland, L. J., & Lamberts, S. W. J. (2004) · KARGER eBooks · doi:10.1159/000079048 · Cited by 76
Kawamata, T., Iseki, H., Ishizaki, R., & Hori, T. (2002) · Neurological Research · doi:10.1179/016164102101199882 · Cited by 76
Contemporary management of prolactinomas
Liu, J. K., & Couldwell, W. T. (2004) · Neurosurgical FOCUS · doi:10.3171/foc.2004.16.4.3 · Cited by 75
Colao, A., Lombardi, G., & Annunziato, L. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.3.555 · Cited by 75
Self-citationGuivarc’h, D., Vincent, J., & Vernier, P. (1998) · Endocrinology · doi:10.1210/endo.139.10.6246 · Cited by 74
Is there an increase in second brain tumours after surgery and irradiation for a pituitary tumour?
Erfurth, E. M., Bülow, B., Mikoczy, Z., Svahn‐Tapper, G., & Hagmar, L. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01385.x · Cited by 74
Colao, A. A. L., Annunziato, L., & Lombardi, G. (1998) · Annals of Medicine · doi:10.3109/07853899809002486 · Cited by 73
Self-citationPregnancy in hyperprolactinemic women
Wallach, E. E., Ruiz-Velasco, V., & Tolis, G. (1984) · Fertility and Sterility · doi:10.1016/s0015-0282(16)47888-x · Cited by 72
Moriondo, P., TRAVAGLINI, P., NISSIM, M., et al. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-4-764 · Cited by 72
Stereotactic radiosurgery for pituitary tumors
Witt, T. C. (2003) · Neurosurgical FOCUS · doi:10.3171/foc.2003.14.5.11 · Cited by 71
HYPERPROLACTINAEMIA IN MEN?RESPONSE TO BROMOCRIPTINE THERAPY
PRESCOTT, R. (1982) · The Lancet · doi:10.1016/s0140-6736(82)90975-8 · Cited by 71
Southgate, T. D., Windeatt, S., Smith-Arica, J. R., Gerdes, C. A., Perone, M. J., Morris, I. D., Davis, J. R., Klatzmann, D., Lowenstein, P. R., & Castro, M. G. (2000) · Endocrinology · doi:10.1210/en.141.9.3493 · Cited by 70
Vlissides, D. N., Gill, D., & Castelow, J. (1978) · BMJ · doi:10.1136/bmj.1.6111.510-a · Cited by 70
Pregnancy in patients presenting with hyperprolactinaemia.
Thorner, M. O., Edwards, C. R. W., Charlesworth, M., Dacie, J. E., MOULT, P. J. A., REES, L. H., Jones, A. E., & BESSER, G. M. (1979) · BMJ · doi:10.1136/bmj.2.6193.771 · Cited by 70
Results of Treatment of Pituitary Disease in Multiple Endocrine Neoplasia, Type I
O’Brien, T., O'Riordan, D., Gharib, H., Scheithauer, B. W., Ebersold, M. J., & van Heerden, J. A. (1996) · Neurosurgery · doi:10.1097/00006123-199608000-00008 · Cited by 69
Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Brue, T. C., Pellegrini, I., Gunz, G., Morange, I., Dewailly, D., Brownell, J., Enjalbert, A., & Jaquet, P. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.3.1346788 · Cited by 68
Vance, M. L., Lipper, M. H., Klibanski, A., Biller, B. M. K., Samaan, N. A., & Molitch, M. E. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-9-668 · Cited by 68
Self-citationThe outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy
Soule, S. G., Farhi, J., Conway, G. S., Jacobs, H. S., & Powell, M. P. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.738559.x · Cited by 68
Long-term effects of aromatase inhibitors on bone
Eastell, R., & Hannon, R. A. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.04.009 · Cited by 67
Cabergoline: Long-Acting Oral Treatment of Hyperprolactinemic Disorders
Ferrari, C. I., MATTEI, A. M., Melis, G. B., et al. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-6-1201 · Cited by 67
Dopaminergic Receptors in Human Prolactin-Secreting Adenomas: A Quantitative Study*
BRESSION, D., Brandi, A., Martres, M., NOUSBAUM, A., Cesselin, F., Racadot, J., & Peillon, F. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-5-1037 · Cited by 66
Esposito, V., Santoro, A., Minniti, G. C., Salvati, M., Innocenzi, G., Lanzetta, G., & Cantore, G. (2004) · Neurological Sciences · doi:10.1007/s10072-004-0351-z · Cited by 66
Alteration of Gα Subunits mRNA Levels in Bromocriptine Resistant Prolactinomas
Caccavelli, L., Morange-Ramos, I., Kordon, C., et al. (1996) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.1996.04902.x · Cited by 66
Residual anterior pituitary function following transsphenoidal resection of pituitary macroadenomas
Nelson, A. T., Tucker, H. S. G., & Becker, D. P. (1984) · Journal of neurosurgery · doi:10.3171/jns.1984.61.3.0577 · Cited by 66
Chaidarun, S., Swearingen, B., & Alexander, J. M. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5128 · Cited by 64
Kukstas, L. A., Domec, C., Bascles, L., Bonnet, J., Verrier, D., Israël, J.-M., & Vincent, J. (1991) · Endocrinology · doi:10.1210/endo-129-2-1101 · Cited by 64
Prolactinoma and body weight: A retrospective study
Creemers, L. B., ZELISSEN, P. M. J., Verlaat, J. W. V. '., & Koppeschaar, H. P. F. (1991) · European Journal of Endocrinology · doi:10.1530/acta.0.1250392 · Cited by 62
Failure of bromocriptine to maintain reduction in size of a macroprolactinoma.
Breidahl, H. D., Topliss, D. J., & Pike, J. W. (1983) · BMJ · doi:10.1136/bmj.287.6390.451 · Cited by 62
Benedetti, M. S., Dostert, P., Barone, D., Efthymiopoulos, C., Peretti, G., & Roncucci, R. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90367-f · Cited by 62
HYPERPROLACTINAEMIA IN MALES WITH AND WITHOUT PITUITARY MACROADENOMAS
Spark, R., OʼReilly, G. V., Wills, C., Ransil, B., & Bergland, R. M. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91094-7 · Cited by 62
Successful Treatment of a Large Macroprolactinoma with Cabergoline During Pregnancy
Liu, C., & Tyrrell, J. (2001) · Pituitary · doi:10.1023/a:1015319007880 · Cited by 61
Senogles, S. E., Heimert, T. L., Odife, E. R., & Quasney, M. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309792200 · Cited by 61
Guadagni, F., Roselli, M., Cosimelli, M., Mannella, E., Tedesco, M., Cavaliere, F., Grassi, A., Abbolito, M. R., Greiner, J. W., & Schlom, J. (1993) · Cancer · doi:10.1002/1097-0142(19931001)72:7<2227::aid-cncr2820720727>3.0.co;2-i · Cited by 61
Testosterone-Related Exacerbation of a Prolactin-Producing Macroadenoma: Possible Role for Estrogen
Prior, J. C., Cox, T.-A., FAIRHOLM, D., Kostashuk, E. C., & NUGENT, R. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-2-391 · Cited by 61
Emergency hypophysectomy in pregnancy after induction of ovulation.
Kajtar, T. J., & Tomkin, G. H. (1971) · BMJ · doi:10.1136/bmj.4.5779.88 · Cited by 60
CV 205–502 Treatment of Hyperprolactinemia*
Vance, M. L., Cragun, J. R., REIMNITZ, C., Chang, R. J., RASHEF, E., Blackwell, R. E., MILLER, M. M., & Molitch, M. E. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-336 · Cited by 60
Self-citationLong-Term Treatment of Prolactin-Secreting Macroadenomas with Pergolide
Freda, P. U., Andreadis, C. B., Khandji, A. G., Khoury, M., Bruce, J. N., Jacobs, T. P., & Wardlaw, S. L. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6329 · Cited by 60
Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient
Serri, O., Noiseux, D., Robert, F., & Hardy, J. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784065 · Cited by 58
Missale, C., Losa, M., Sigala, S., Balsari, A., Giovanelli, M. A., & Spano, P. (1996) · Molecular Endocrinology · doi:10.1210/mend.10.3.8833656 · Cited by 58
Duranteau, L., Chanson, P., Lavoinne, A., Horlait, S., Lubetzki, J., & Kuhn, J. M. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb01731.x · Cited by 58
Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy
Garcia, M., & Kapcala, L. P. (1995) · Journal of Endocrinological Investigation · doi:10.1007/bf03349744 · Cited by 58
Results of surgery in 114 patients with prolactin-secreting pituitary adenomas
Domingue, J. N., Richmond, I. L., & Wilson, C. B. (1980) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(80)90392-0 · Cited by 57
Chaidarun, S., & Alexander, J. M. (1998) · Molecular Endocrinology · doi:10.1210/me.12.9.1355 · Cited by 56
Buelke‐Sam, J., Bryant, H. U., & Francis, P. C. (1998) · Reproductive Toxicology · doi:10.1016/s0890-6238(98)00003-3 · Cited by 54
van der Lely, A. J., Brownell, J., & Lamberts, S. W. J. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-5-1136 · Cited by 54
Pascal-Vigneron, V., Weryha, G., Bosc, M., & Leclere, J.-C. (1995) · PubMed · Cited by 53
Murphy, F. Y., Vesely, D. L., Jordan, R. M., Flanigan, S., & Kohler, P. O. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90668-1 · Cited by 53
Lamberts, S. W. J., & Quik, R. F. P. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-3-635 · Cited by 51
Homburg, R., West, C. R., Brownell, J., & Jacobs, H. S. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb00899.x · Cited by 51
Prolactinomas in Men: Clinical Characteristics and the Effect of Bromocriptine Treatment
Hulting, A. L., Muhr, C., Lundberg, P. O., et al. (1985) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1985.tb01642.x · Cited by 50
Radiotherapy for Non-Functioning Pituitary Tumors—When and Under What Circumstances?
Gittoes, N. J. L. (2003) · Pituitary · doi:10.1023/b:pitu.0000004801.95086.e2 · Cited by 50
Cai, A., Hayes, J. D., Patel, N., & Hyde, J. F. (1999) · Endocrinology · doi:10.1210/endo.140.11.7120 · Cited by 50
Walsh, J. P., & Pullan, P. T. (1997) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1997.tb02196.x · Cited by 49
LONG‐TERM FOLLOW‐UP OF‘CURED’PROLACTINOMA PATIENTS AFTER SUCCESSFUL ADENOMECTOMY
CICCARELLI, E., Ghigo, E., Miola, C., Gandini, G., Müller, E. E., & Camanni, F. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb00901.x · Cited by 49
Andreotti, A. C., Pianezzola, E., Persiani, S., Pacciarini, M. A., Benedetti, M. S., & Pontiroli, A. E. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.3.841 · Cited by 49
Pituitary disorders during pregnancy.
Molitch, M. (2006) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2005.09.011 · Cited by 48
Self-citationIshibashi, M., & YAMAJI, T. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-5-985 · Cited by 46
Return of Gonadal Function in Men with Prolactin-Secreting Pituitary Tumors*
Murray, F. T., Cameron, D. F., & KETCHUM, C. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-1-79 · Cited by 45
Microprolactinomas in males treated by transsphenoidal surgery
Wolfsberger, S., Czech, T., Vierhapper, H., Benavente, R., & Knosp, E. (2003) · Acta Neurochirurgica · doi:10.1007/s00701-003-0134-y · Cited by 45
Closse, A., Camps, M., Wanner, A., & Palacios, J. M. (1988) · Brain Research · doi:10.1016/0006-8993(88)91164-x · Cited by 45
Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males
Colao, A., Rosa, M. D., Sarnacchiaro, F., Sarno, A. D., Landi, M. L., Iervolino, E., Zarrilli, S., Merola, B., & Lombardi, G. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1350548 · Cited by 45
Self-citationTreatment of hyperprolactinemic amenorrhea with pulsatile gonadotropin-releasing hormone therapy
Gindoff, P. R., Loucopoulos, A., & Jewelewicz, R. (1986) · Fertility and Sterility · doi:10.1016/s0015-0282(16)49899-7 · Cited by 45
Frans, E., Dom, R., & Demedts, M. (1992) · European Respiratory Journal · doi:10.1183/09031936.93.05020263 · Cited by 44
Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy
Kovács, K., Ştefăneanu, L., Horváth, É., Buchfelder, M., Fahlbusch, R., & Becker, W. (1995) · Journal of neurosurgery · doi:10.3171/jns.1995.82.5.0886 · Cited by 43
D 2 Dopaminergic Receptors: Normal and Abnormal Transduction Mechanisms
Caccavelli, L., Cussac, D., Pellegrini, I., Audinot, V., Jaquet, P., & Enjalbert, A. (2008) · Hormone Research · doi:10.1159/000182494 · Cited by 43
Late Development of Resistance to Bromocriptine in a Patient with Macroprolactinoma
Delgrange, E., Crabbé, J., & Donckier, J. E. (1998) · Hormone Research in Paediatrics · doi:10.1159/000023180 · Cited by 42
Murabe, H., Shimatsu, A., Ihara, C., Mizuta, H., Nakamura, Y., Nagata, I., Kikuchi, H., & Nakao, K. (1996) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.1996.04996.x · Cited by 42
The Effect of Combined Estrogen/Progestogen Treatment in Women with Hyperprolactinemic Amenorrhea
Fahy, U., Foster, P. A., Torode, H. W., Hartog, M., & Hull, M. G. R. (1992) · Gynecological Endocrinology · doi:10.3109/09513599209015553 · Cited by 41
Johnston, D. G., Hall, K., Kendall-Taylor, P., ROSS, W. M., Crombie, A. L., Cook, D. B., & Watson, M. J. (1986) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1986.tb01664.x · Cited by 41
Prolactin secreting adenoma in 22 men.
Grisoli, F., Vincentelli, F., Jaquet, P., et al. (1980) · PubMed · Cited by 41
Giant prolactinomas presenting as skull base tumors
Minniti, G. C., Jaffrain‐Rea, M., Santoro, A., et al. (2002) · Surgical Neurology · doi:10.1016/s0090-3019(01)00697-8 · Cited by 40
Stereotactic Radiosurgery: The Lyon Experience
Rocher, F., Sentenac, I., Berger, C., Marquis, I., Romestaing, P., & Gérard, J. P. (1995) · Springer eBooks · doi:10.1007/978-3-7091-9399-0_21 · Cited by 39
Soonawala, R. P. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92550-1 · Cited by 39
p16 (INK4a, MTS‐1) gene polymorphism and methylation status in human pituitary tumours
Jaffrain‐Rea, M., Ferretti, E., Toniato, E., Cannita, Santoro, A., Stefano, M. D., Ricevuto, E., Maroder, Tamburrano, Cantore, et al. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00774.x · Cited by 39
Antiparkinsonian treatment in pregnancy
Mari, M. D., Zenzola, A., & Lamberti, P. (2002) · Movement Disorders · doi:10.1002/mds.10040 · Cited by 39
Nerve growth factor promotes the differentiation of pituitary mammotroph cells in vitro
Missale, C., Boroni, F., Frassine, M., Caruso, A., & Spano, P. (1995) · Endocrinology · doi:10.1210/endo.136.3.7867574 · Cited by 39
Williams, J. C., Stone, D., Smith-Arica, J. R., Morris, I. D., Lowenstein, P. R., & Castro, M. G. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0499 · Cited by 39
Cerebrospinal Fluid Rhinorrhea: A Complication of Therapy for Invasive Prolactinomas
Landolt, A. M. (1982) · Neurosurgery · doi:10.1227/00006123-198209000-00010 · Cited by 39
Prolactin-Secreting Macroadenomas in Adolescents: Response to Bromocriptine Therapy
Tyson, D., Reggiardo, D., Sklar, C., & David, R. (1993) · American journal of diseases of children · doi:10.1001/archpedi.1993.02160340043011 · Cited by 38
Pergolide As Primary Therapy for Macroprolactinomas
Orrego, J. J., Chandler, W. F., & Barkan, A. L. (2000) · Pituitary · doi:10.1023/a:1012836331506 · Cited by 37
Hyperprolactinaemia as a reversible cause of weight gain in male patients?
Delgrange, E., Donckier, J. E., & Maiter, D. M. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00700.x · Cited by 37
Nerve Growth Factor in Pituitary Development and Pituitary Tumors
Missale, C., & Spano, P. (1998) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1998.0165 · Cited by 37
Nielsen, S., Mellemkjær, S., Rasmussen, L. M., Ledet, T., Astrup, J., Weeke, J., & Jørgensen, J. O. L. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5046 · Cited by 37
Cerebrospinril fluid rhinorrhea during treatment with bromocriptine for prolactinoma
Kok, J. G., Bartelink, A. K. M., Schulte, B. P. M., SMALS, A. G. H., PIETERS, G. F. F. M., Meyer, E., & Merx, H. (1985) · Neurology · doi:10.1212/wnl.35.8.1193 · Cited by 36
Pregnancy after treatment in patients with prolactinoma: Operation versus bromocriptine
Samaan, N. A., Schultz, P. N., Leavens, T. A., Leavens, M. E., & Lee, Y. Y. (1986) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(86)90164-x · Cited by 36
Abnormal Transduction Mechanisms in Pituitary Adenomas
Barlier, A., Pellegrini, I., Caccavelli, L., Gunz, G., Morange, I., Jaquet, P., & Enjalbert, A. (1997) · Hormone Research · doi:10.1159/000185468 · Cited by 35
Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases
DALLABONZANA, D., SPELTA, B., OPPIZZI, G., Tonon, C., Luccarelli, G., Chiodini, P. G., & Liuzzi, A. (1983) · Journal of Endocrinological Investigation · doi:10.1007/bf03350560 · Cited by 35
Outcome of pregnancies in women with treated or untreated hyperprolactinemia
Rossi, A.-M., Vilska, S., & Heinonen, P. K. (1995) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0301-2115(95)02257-0 · Cited by 35
Late recurrence of surgically removed prolactinomas
Parl, F. F., Cruz, V. E., Cobb, C. A., Bradley, C., & Aleshire, S. L. (1986) · Cancer · Cited by 34
Prolactin Receptor Messenger Ribonucleic Acid in Normal and Neoplastic Human Pituitary Tissues
Jin, L. G., Qian, X., Kulig, E., Scheithauer, B., Calle-Rodrigue, R., Abboud, C. F., Davis, D. H., Kovács, K., & Lloyd, R. V. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3815 · Cited by 34
Prolactin-secreting pituitary adenomas: neurosurgical management of 37 patients
Woosley, R. E., King, J. S., & Talbert, L. M. (1982) · Fertility and Sterility · doi:10.1016/s0015-0282(16)45977-7 · Cited by 34
Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs
Simard, J., & Labrie, F. (1985) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(85)90131-5 · Cited by 33
Jewelewicz, R., Zimmerman, E. A., & Carmel, P. W. (1977) · Fertility and Sterility · doi:10.1016/s0015-0282(16)42314-9 · Cited by 33
Pontiroli, A. E., Viberti, G., Mangili, R., Cammelli, L., & Dubini, A. (1987) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1987.tb03072.x · Cited by 32
Smith-Arica, J. R., Williams, J. C., Stone, D., Smith, J. M., Lowenstein, P. R., & Castro, M. G. (2001) · Endocrinology · doi:10.1210/endo.142.6.8183 · Cited by 32
Popadić, A., Witzmann, A., Buchfelder, M., Eiter, H., & Komminoth, P. (1999) · Surgical Neurology · doi:10.1016/s0090-3019(97)00458-8 · Cited by 30
Transnasal surgery for prolactin-secreting pituitary adenomas in childhood and adolescence
Abe, T., & Lüdecke, D. K. (2002) · Surgical Neurology · doi:10.1016/s0090-3019(02)00714-0 · Cited by 30
Bromocriptine-induced psychosis in acromegaly.
Feuvre, C. M. L., Isaacs, A., & Frank, O. S. (1982) · BMJ · doi:10.1136/bmj.285.6351.1315 · Cited by 30
Cure of Hypogonadism after Removal of Prolactin-Secreting Adenomas in Men*
Arafah, B. M., Manni, A., Brodkey, J. S., Kaufman, B., Velasco, M., & Pearson, O. H. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-1-91 · Cited by 30
The Behavioral Toxicity of Bromocriptine in Patients with Psychiatric Illness
Perovich, R., Lieberman, J. A., Fleischhacker, W. W., & Alvir, J. (1989) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198912000-00006 · Cited by 30
The role of gamma knife radiosurgery in the management of pituitary adenomas
Thorén, M. C., Höybye, C., Grenbäck, E., Degerblad, M., Rähn, T., & Hulting, A. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1012926022229 · Cited by 29
Harrington, M. H., & Casella, S. J. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32834ed6b9 · Cited by 29
Radwańska, E., McGarrigle, H. H. G., Little, V., Lawrence, D. M., Sarris, S., & Swyer, G. I. M. (1979) · Fertility and Sterility · doi:10.1016/s0015-0282(16)44178-6 · Cited by 28
Intracranial dissemination of a macroprolactinoma
Assies, J., Verhoeff, N. P. L. G., Bosch, D. A., & Hofland, L. J. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb00351.x · Cited by 28
Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas
George, L., Nicolau, N., Scanlon, M., & Davies, J. S. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01137.x · Cited by 28
Treatment of extensively invasive (giant) prolactinomas with bromocriptine.
Grebe, S. K., DeLaHunt, J., & Feek, C. M. (1992) · PubMed · Cited by 28
Estrogens and the genetic control of tumor growth.
Gorski, J., Wendell, D. L., Gregg, D. W., & Chun, T.-Y. (1997) · PubMed · Cited by 28
Missale, C., Losa, M., Boroni, F., Giovanelli, M. A., Balsari, A., & Spano, P. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.520 · Cited by 26
Restoration of LH pulsatility in patients with prolactinomas after trans-sphenoidal surgery
Koizumi, K., Aono, T., Koike, K., & Kurachi, K. (1984) · European Journal of Endocrinology · doi:10.1530/acta.0.1070433 · Cited by 26
Ishibashi, M., & YAMAJI, T. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-3-599 · Cited by 25
Arafah, B. M., Brodkey, J. S., & Pearson, O. H. (1986) · Metabolism · doi:10.1016/0026-0495(86)90052-1 · Cited by 25
Rush, S. C., Kupersmith, M. J., Lerch, I. A., Cooper, P. R., Ransohoff, J., & Newall, J. (1990) · Journal of neurosurgery · doi:10.3171/jns.1990.72.4.0594 · Cited by 25
Molecular therapeutics: promise and challenges
Kohn, E. C., Lu, Y., Wang, H., Yu, Q., Yu, S., Hall, H. S., Smith, D. L., Meric‐Bernstam, F., Hortobágyi, G. N., & Mills, G. B. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.01.009 · Cited by 24
Davis, J. R., McVerry, J., Lincoln, G. A., Windeatt, S., Lowenstein, P. R., Castro, M. G., & McNeilly, A. S. (2001) · Endocrinology · doi:10.1210/en.142.2.795 · Cited by 24
FAILURE OF PROPHYLACTIC SURGERY TO AVERT MASSIVE PITUITARY EXPANSION IN PREGNANCY
Belchetz, P. E., CARTY, A., Clearkin, L. G., Davis, J. C., Jeffreys, R. V., & Rae, P. G. (1986) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1986.tb01698.x · Cited by 24
Narita, O., Kimura, T., Suganuma, N., Osawa, M., Mizutani, S., Masahashi, T., Asai, M., & Tomoda, Y. (1985) · PubMed · Cited by 23
Razzaq, R., Halloran, D. J. O. R., Beardwell, C. G., et al. (2008) · Hormone Research · doi:10.1159/000182739 · Cited by 23
Lasco, A., Cannavò, S., Gaudio, A., Morabito, N., Basile, G., Nicita-Mauro, V., & Frisina, N. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470461 · Cited by 22
G proteins in normal rat pituitaries and in prolactin-secreting rat pituitary tumors
Bouvier, C., Forget, H., Lagacé, G., Drews, R. T., Sinnett, D., Labuda, D., & COLLU, R. (1991) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(91)90183-s · Cited by 21
Facchetti, M., Uberti, D. L., Memo, M., & Missale, C. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0190 · Cited by 20
Nguyen, C. B., Harris, L., Szönyi, É., Baughman, S. A., Hale, V. G., Dybdal, N. O., Sadick, M. D., & Escandón, E. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15106-9 · Cited by 19
Stevenaert, A., Beckers, A. M., Vandalem, J. L., & Hennen, G. P. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-5-1044 · Cited by 19
Bergh, T., Skarin, G., Nillius, S. J., & WIDE, L. E. (1985) · European Journal of Endocrinology · doi:10.1530/acta.0.1100440 · Cited by 19
Tan, S. L., & Jacobs, H. S. (1986) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(86)90099-8 · Cited by 18
Gaillard, R. C., & Brownell, J. (1988) · Life Sciences · doi:10.1016/0024-3205(88)90301-3 · Cited by 18
Höfle, G., Gasser, R. W., Mohsenipour, I., & FINKENSTEDT, G. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211978 · Cited by 18
Additional Insights Into Pergolide-Associated Valvular Heart Disease
Lanier, W. L. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.6.684 · Cited by 18
Prolactin Receptor Messenger Ribonucleic Acid in Normal and Neoplastic Human Pituitary Tissues
Jin, L. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.963 · Cited by 18
Bromocriptine-associated hyponatraemia in cirrhosis.
Marshall, A. W., Jakobovits, A. W., & Morgan, M. Y. (1982) · BMJ · doi:10.1136/bmj.285.6354.1534 · Cited by 17
Potential of Gene Therapy for the Treatment of Pituitary Tumors
Goya, R. G., Sarkar, D. K., Brown, O. A., & Hereñú, C. B. (2004) · Current Gene Therapy · doi:10.2174/1566523044578086 · Cited by 16
Gónzalez, D., Bellido, C., Aguilar, R., Garrido-Gracia, J. C., Hernández, G., Alonso, R., & Sánchez‐Criado, J. E. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01270-2 · Cited by 15
Beckers, A. M., Pétrossians, P., Abs, R., Flandroy, P., Stadnik, T. W., Longueville, M. D., LANCRANJAN, I., & Stevenaert, A. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.1.275 · Cited by 15
Gene therapy for pituitary tumors: from preclinical models to clinical implementation
Castro, M. G., Goverdhana, S., Hu, J., Jovel, N., Yuan, X., & Lowenstein, P. R. (2003) · Frontiers in Neuroendocrinology · doi:10.1016/s0091-3022(02)00106-1 · Cited by 10
Fulvestrant – a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer
Possinger, K. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.12.2549 · Cited by 10
Is pituitary gene therapy realistic?
Davis, J. R., & McNeilly, A. S. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01400.x · Cited by 8
Colao, A., & Pirchio, R. (2021) · Cited by 5
Self-citation
Cited by
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844
Diagnosis and Treatment of Pituitary Adenomas: A Review
Molitch, M. E. (2017) · JAMA · doi:10.1001/jama.2016.19699 · Cited by 933
Self-citationWhat Can We Learn from Rodents about Prolactin in Humans?
Ben-Jonathan, N., LaPensee, C. R., & LaPensee, E. W. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0017 · Cited by 523
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
Briet, C., Salenave, S., Bonneville, J.-F., Laws, E. R., & Chanson, P. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1042 · Cited by 409
Metadata
- Authors
- Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2006-05-26
- Volume
- 27
- Issue
- 5
- Pages
- 485-534
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2017283375
- Cited by
- 824
- References
- 376
- FWCI
- 24.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.